display

Augsburg / Tübingen (dpa) - The Tübingen biotech company Curevac hopes to be able to use its corona vaccine this summer through its cooperation with the pharmaceutical company Bayer.

“We hope that our vaccine will be approved and used in the middle of the current year or in the third quarter,” said Curevac spokesman Thorsten Schüller of “Augsburger Allgemeine” (Friday).

It is still unclear whether Bayer will also take over the manufacture of the vaccine in addition to helping to develop it ready for the market, it said.

A production of the vaccine is not part of the current cooperation agreement.

However, Bayer has promised to examine whether it would be possible to manufacture the vaccine in its production facilities, the spokesman said.

Curevac announced on Thursday that it had signed a cooperation and service agreement with the pharmaceutical company Bayer. Curevac has been developing a vaccine for a long time, but the market approval is not yet in sight. Bayer is now to help with the complex work for approval and for the necessary study and also keep an eye on the supply chains.